Coordinating Minister for Economic Affairs Airlangga Hartarto stated that 30 million doses of COVID-19 vaccine will be received by Indonesia in the fourth quarter of this year so that the first quarter of next year can be vaccinated.

"They have committed to giving 30 million in the fourth quarter of 2020 so that in the first quarter next year we can vaccinate subjects after success in testing clinical trials," he said in an online discussion in Jakarta, Tuesday.

Airlangga, who is also Head of the Committee for Handling COVID-19 and National Economic Recovery (PEN), said the government itself is targeting Indonesia to have access to between 250 million and 300 million doses of the COVID-19 vaccine by next year.

"The government has conducted clinical trials of vaccines not only in Indonesia but also in China, Brazil, Bangladesh, and Turkey. We expect to complete this in December (2020)," he said.

He explained that the target would be achieved through 10 sources, namely Sinovac, G-42 / Wuhan Institute Biological Products / Sinopharm, Astra Zaneca, GAVI / CEPI, and CanSino Biological Inc./Beijing Institute Technology.

"The price of the vaccine from GAVI / CEPI is estimated to be lower by around $3 to $5, while for Sinovac between $10 and $20," he explained.

Then also from BioNTech / Fosun Pharma / Pfizer, Modena / NIAID (National Institute of Allergy and Infection Diseases, Acturus Therapeutics / Duke-NUS, Korean Genexine, and Merah Putih Vaccine.

"The development of our own vaccine, namely the Merah Putih vaccine, is expected to be included in the third phase in the third quarter of 2021," he said.

He said some of the vaccines only need one injection and some are injected twice.

"Sinopharm, might need one injection, so the method and price will be different," he said. (Antaranews)